Abstract
Normal bone homeostasis is the result of a cross-talk between the anabolic axis (osteoblast differentiation) and catabolic axis (osteoclast remodeling). A disruption of this tightly regulated relationship leads to imbalanced bone turnover which ultimately results in diseases of the skeleton. Given that the majority of disease states are characterized by an inadequate renewal of osteoblasts, and the canonical wingless (Wnt) pathway is critical for their differentiation from progenitors, this represents an intriguing target for bone therapy. This mini-review focuses on the different options available for pharmaceutical enhancement of osteogenic differentiation through targeting the various proteins involved in Wnt signaling.
Keywords: Dkk-1, glycogen-synthetase-kinase-3β, mesenchymal stem/progenitor cell, osteogenic differentiation, Wnt-signaling
Current Molecular Pharmacology
Title:Potential of Modulating Wnt Signaling Pathway Toward the Development of Bone Anabolic Agent
Volume: 5
Author(s): Ulf Krause and Carl A. Gregory
Affiliation:
Keywords: Dkk-1, glycogen-synthetase-kinase-3β, mesenchymal stem/progenitor cell, osteogenic differentiation, Wnt-signaling
Abstract: Normal bone homeostasis is the result of a cross-talk between the anabolic axis (osteoblast differentiation) and catabolic axis (osteoclast remodeling). A disruption of this tightly regulated relationship leads to imbalanced bone turnover which ultimately results in diseases of the skeleton. Given that the majority of disease states are characterized by an inadequate renewal of osteoblasts, and the canonical wingless (Wnt) pathway is critical for their differentiation from progenitors, this represents an intriguing target for bone therapy. This mini-review focuses on the different options available for pharmaceutical enhancement of osteogenic differentiation through targeting the various proteins involved in Wnt signaling.
Export Options
About this article
Cite this article as:
Krause Ulf and A. Gregory Carl, Potential of Modulating Wnt Signaling Pathway Toward the Development of Bone Anabolic Agent, Current Molecular Pharmacology 2012; 5 (2) . https://dx.doi.org/10.2174/1874467211205020164
DOI https://dx.doi.org/10.2174/1874467211205020164 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Thymidine Kinase-Mediated Shut Down of Bone Morphogenetic Protein-4 Expression Allows Regulated Bone Production
Current Gene Therapy Multifunctional Hydroxyapatite-based Nanoparticles for Biomedicine: Recent Progress in Drug Delivery and Local Controlled Release
Current Mechanics and Advanced Materials Anti-Tumor Activity of Non-Nucleosidic Reverse Transcriptase Inhibitors
Current Pharmaceutical Design Targeting Tumor Suppressor p53 for Cancer Therapy: Strategies, Challenges and Opportunities
Current Drug Targets Imaging Virus-Associated Cancer
Current Pharmaceutical Design Key Questions in Metastasis: New Insights in Molecular Pathways and Therapeutic Implications
Current Pharmaceutical Biotechnology Signal Transducer and Activator of Transcription 3 Signaling Pathway: A Potential Target in Sarcoma Treatment
Current Enzyme Inhibition Sida cordifolia, a Traditional Herb in Modern Perspective – A Review
Current Traditional Medicine Inorganic Phosphate as a Signaling Molecule: A Potential Strategy in Osteosarcoma Treatment
Current Pharmaceutical Design Drugs of Abuse: Epigenetic Mechanisms in Toxicity and Addiction
Current Medicinal Chemistry Vitamin D Analogs in Cutaneous Malignancies
Current Pharmaceutical Design The Dichloromethane Fraction of <i>Vernonia cinerea</i> Impart Pro-Apoptotic, Genotoxic, Cell Cycle Arrest, and Drug Efflux Inhibitory Effects on Human Adenocarcinoma Cells
Recent Patents on Anti-Cancer Drug Discovery Specific Targeting of Akt Kinase Isoforms: Taking the Precise Path for Prevention and Treatment of Cancer
Current Drug Targets Alpha-Particle Microdosimetry
Current Radiopharmaceuticals Nanomedicine to Deal With Cancer Cell Biology in Multi-Drug Resistance
Mini-Reviews in Medicinal Chemistry Genetic and Epigenetic Signatures in Human Hepatocellular Carcinoma:A Systematic Review
Current Genomics Pathophysiology and Pharmacological Targeting of Tumor-Induced Bone Disease: Current Status and Emerging Therapeutic Interventions
Current Medicinal Chemistry Tumor-Targeting Peptides: Ligands for Molecular Imaging and Therapy
Anti-Cancer Agents in Medicinal Chemistry Aluminofluoride Complexes: Phosphate Analogues and a Hidden Hazard for Living Organisms
Current Inorganic Chemistry (Discontinued) Role of the Receptor Tyrosine Kinase Axl and its Targeting in Cancer Cells
Current Medicinal Chemistry